A phase 1 study evaluating the pharmacokinetics (PK) and safety of regorafenib (REG) in patients with advanced solid tumors with severe renal impairment (SRI) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Renouf, DJ
  • Hirte, Holger
  • O'Bryant, CL
  • Trnkova, ZJ
  • Cleton, A
  • Huang, F
  • Mueller, U
  • Ayoub, J-P
  • Lockhart, AC
  • Quinn, DI
  • Dy, GK
  • Sawyer, MB

publication date

  • October 2016